{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:50:56Z","timestamp":1792785056450,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":92,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Iran University of Medical Sciences","award":["19456"],"award-info":[{"award-number":["19456"]}],"id":[{"id":"https:\/\/ror.org\/03w04rv71","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Iran University of Medical Sciences","award":["19456"],"award-info":[{"award-number":["19456"]}],"id":[{"id":"https:\/\/ror.org\/03w04rv71","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-62555-7","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T03:04:17Z","timestamp":1784084657000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Expression of the switch receptor PD1\/IL15R\u03b2 in MSLN-CAR-T cells overcomes PD1\/PDL1 signaling in solid tumors"],"prefix":"10.1038","volume":"16","author":[{"given":"Zahra","family":"Shahosseini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahereh","family":"Soltantoyeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid Reza","family":"Mirzaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayhan","family":"Azadmanesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Arashkia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamshid","family":"Hadjati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9494-2530","authenticated-orcid":false,"given":"Mohammad M.","family":"Farajollahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"issue":"6","key":"62555_CR1","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1007\/s11596-019-2118-z","volume":"39","author":"X Yang","year":"2019","unstructured":"Yang, X., Wang, G. X. & Zhou, J. F. CAR T Cell Therapy for Hematological Malignancies. Curr. Med. Sci. 39(6), 874\u2013882 (2019).","journal-title":"Curr. Med. Sci."},{"key":"62555_CR2","doi-asserted-by":"crossref","unstructured":"Mishra, A. K. et al. Emerging trends in immunotherapy for cancer. Diseases  10(3)  (2022).","DOI":"10.3390\/diseases10030060"},{"issue":"261","key":"62555_CR3","doi-asserted-by":"publisher","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","volume":"6","author":"PS Adusumilli","year":"2014","unstructured":"Adusumilli, P. S. et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci. Transl Med. 6(261), 261ra151 (2014).","journal-title":"Sci. Transl Med."},{"key":"62555_CR4","doi-asserted-by":"crossref","unstructured":"Watanabe, K. et al. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. JCI Insight 3(7)  (2018).","DOI":"10.1172\/jci.insight.99573"},{"issue":"2","key":"62555_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ccell.2020.11.005","volume":"39","author":"S Srivastava","year":"2021","unstructured":"Srivastava, S. et al. Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade. Cancer Cell. 39(2), 193\u2013208e10 (2021).","journal-title":"Cancer Cell."},{"issue":"2","key":"62555_CR6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","volume":"6","author":"A Morello","year":"2016","unstructured":"Morello, A., Sadelain, M. & Adusumilli, P. S. Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors. Cancer Discov. 6(2), 133\u2013146 (2016).","journal-title":"Cancer Discov"},{"issue":"2","key":"62555_CR7","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00262-022-03238-w","volume":"72","author":"J Chen","year":"2023","unstructured":"Chen, J. et al. Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer. Cancer Immunol. Immunother. 72(2), 409\u2013425 (2023).","journal-title":"Cancer Immunol. Immunother"},{"key":"62555_CR8","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.3389\/fimmu.2018.02166","volume":"9","author":"M Akce","year":"2018","unstructured":"Akce, M. et al. The Potential of CAR T Cell Therapy in Pancreatic Cancer. Front. Immunol. 9, 2166 (2018).","journal-title":"Front. Immunol."},{"issue":"1","key":"62555_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","volume":"120","author":"N Tokarew","year":"2019","unstructured":"Tokarew, N. et al. Teaching an old dog new tricks: next-generation CAR T cells. Br. J. Cancer. 120(1), 26\u201337 (2019).","journal-title":"Br. J. Cancer"},{"issue":"1","key":"62555_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","volume":"52","author":"PS Hegde","year":"2020","unstructured":"Hegde, P. S. & Chen, D. S. Top 10 Challenges in Cancer Immunotherapy. Immunity 52(1), 17\u201335 (2020).","journal-title":"Immunity"},{"issue":"10","key":"62555_CR11","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.jcyt.2018.07.005","volume":"20","author":"SN Zolov","year":"2018","unstructured":"Zolov, S. N., Rietberg, S. P. & Bonifant, C. L. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells. Cytotherapy 20(10), 1259\u20131266 (2018).","journal-title":"Cytotherapy"},{"issue":"1","key":"62555_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","volume":"15","author":"JR Westin","year":"2014","unstructured":"Westin, J. R. et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 15(1), 69\u201377 (2014).","journal-title":"Lancet Oncol."},{"key":"62555_CR13","doi-asserted-by":"crossref","unstructured":"Sui, H. et al. Anti-PD-1\/PD-L1 Therapy for non-small-cell lung cancer: Toward personalized medicine and combination strategies. J. Immunol. Res. 2018, 6984948  (2018).","DOI":"10.1155\/2018\/6984948"},{"key":"62555_CR14","doi-asserted-by":"crossref","unstructured":"Bell, M. & Gottschalk, S. Engineered cytokine signaling to improve CAR T cell effector function. Front. Immunol.  12  (2021).","DOI":"10.3389\/fimmu.2021.684642"},{"issue":"1","key":"62555_CR15","doi-asserted-by":"publisher","first-page":"12506","DOI":"10.1038\/s41598-022-16616-2","volume":"12","author":"L Li","year":"2022","unstructured":"Li, L. et al. Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells. Sci. Rep. 12(1), 12506 (2022).","journal-title":"Sci. Rep."},{"issue":"6","key":"62555_CR16","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1158\/2326-6066.CIR-15-0276","volume":"4","author":"GA Rufener","year":"2016","unstructured":"Rufener, G. A. et al. Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab. Cancer Immunol. Res. 4(6), 509\u2013519 (2016).","journal-title":"Cancer Immunol. Res."},{"issue":"Supplement 1","key":"62555_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1182\/blood-2021-146638","volume":"138","author":"NN Shah","year":"2021","unstructured":"Shah, N. N. et al. Phase 1\/2 Trial of IL7\/IL15-Expanded Bispecific LV20.19 CAR T-Cells for Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma. Blood 138(Supplement 1), 95\u201395 (2021).","journal-title":"Blood"},{"key":"62555_CR18","doi-asserted-by":"publisher","first-page":"880108","DOI":"10.3389\/fimmu.2022.880108","volume":"13","author":"H Mu-Mosley","year":"2022","unstructured":"Mu-Mosley, H. et al. Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models. Front. Immunol. 13, 880108 (2022).","journal-title":"Front. Immunol."},{"issue":"11","key":"62555_CR19","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1158\/2159-8290.CD-17-0538","volume":"7","author":"T Shum","year":"2017","unstructured":"Shum, T. et al. Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells. Cancer Discov. 7(11), 1238\u20131247 (2017).","journal-title":"Cancer Discov"},{"issue":"3","key":"62555_CR20","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nm.4478","volume":"24","author":"Y Kagoya","year":"2018","unstructured":"Kagoya, Y. et al. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat. Med. 24(3), 352\u2013359 (2018).","journal-title":"Nat. Med."},{"key":"62555_CR21","doi-asserted-by":"publisher","first-page":"728962","DOI":"10.3389\/fimmu.2021.728962","volume":"12","author":"Y Sun","year":"2021","unstructured":"Sun, Y. et al. CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report. Front. Immunol. 12, 728962 (2021).","journal-title":"Front. Immunol."},{"issue":"4","key":"62555_CR22","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41551-023-01143-w","volume":"8","author":"M Bell","year":"2024","unstructured":"Bell, M. et al. Modular chimeric cytokine receptors with leucine zippers enhance the antitumour activity of CAR T cells via JAK\/STAT signalling. Nat. Biomedical Eng. 8(4), 380\u2013396 (2024).","journal-title":"Nat. Biomedical Eng."},{"key":"62555_CR23","doi-asserted-by":"publisher","first-page":"115740","DOI":"10.1016\/j.biopha.2023.115740","volume":"168","author":"Y Zhou","year":"2023","unstructured":"Zhou, Y. et al. Co-expression of IL-4\/IL-15-based inverted cytokine receptor in CAR-T cells overcomes IL-4 signaling in immunosuppressive pancreatic tumor microenvironment. Biomed. Pharmacother. 168, 115740 (2023).","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"62555_CR24","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","volume":"7","author":"D Alizadeh","year":"2019","unstructured":"Alizadeh, D. et al. IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype. Cancer Immunol. Res. 7(5), 759\u2013772 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"62555_CR25","doi-asserted-by":"publisher","first-page":"104645","DOI":"10.1016\/j.dci.2023.104645","volume":"141","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y. & Su, J. Interleukin-2 family cytokines: An overview of genes, expression, signaling and functional roles in teleost. Dev. Comp. Immunol. 141, 104645 (2023).","journal-title":"Dev. Comp. Immunol."},{"issue":"1","key":"62555_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1600-065X.2012.01150.x","volume":"249","author":"GJW van der Windt","year":"2012","unstructured":"van der Windt, G. J. W. & Pearce, E. L. Metabolic switching and fuel choice during T-cell differentiation and memory development. Immunol. Rev. 249(1), 27\u201342 (2012).","journal-title":"Immunol. Rev."},{"issue":"9","key":"62555_CR27","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1158\/1078-0432.CCR-18-1811","volume":"25","author":"Y Chen","year":"2019","unstructured":"Chen, Y. et al. Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15. Clin. Cancer Res. 25(9), 2915\u20132924 (2019).","journal-title":"Clin. Cancer Res."},{"issue":"48","key":"62555_CR28","doi-asserted-by":"publisher","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","volume":"113","author":"LV Hurton","year":"2016","unstructured":"Hurton, L. V. et al. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc. Natl. Acad. Sci. 113(48), E7788\u2013E7797 (2016).","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"7","key":"62555_CR29","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1158\/2326-6066.CIR-16-0376","volume":"5","author":"G Krenciute","year":"2017","unstructured":"Krenciute, G. et al. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13R\u03b12-CAR T Cells but Results in Antigen Loss Variants. Cancer Immunol. Res. 5(7), 571\u2013581 (2017).","journal-title":"Cancer Immunol. Res."},{"issue":"1_Supplement","key":"62555_CR30","doi-asserted-by":"publisher","first-page":"6805","DOI":"10.4049\/jimmunol.210.Supp.68.05","volume":"210","author":"A Amador","year":"2023","unstructured":"Amador, A. et al. CAR T-cell intrinsic PD1 Dominant Negative Receptor (PD1DNR) functions by both cell-intrinsic and extrinsic mechanisms. J. Immunol. 210(1_Supplement), 6805\u20136805 (2023).","journal-title":"J. Immunol."},{"issue":"7","key":"62555_CR31","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1073\/pnas.1211560110","volume":"110","author":"JP Defour","year":"2013","unstructured":"Defour, J. P. et al. Tryptophan at the transmembrane\u2013cytosolic junction modulates thrombopoietin receptor dimerization and activation. Proc. Natl. Acad. Sci. 110(7), 2540\u20132545 (2013).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"62555_CR32","unstructured":"Regina.Iunhui, VAN BLARCOM. PANOWSKI, S. S. & Barbar Johnson CHIMERIC CYTOKINE RECEPTORS BEARING A PD-I ECTODOMAIN, in WIPO (USA, 2020)."},{"issue":"6","key":"62555_CR33","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1074\/jbc.M115.696534","volume":"291","author":"E Leroy","year":"2016","unstructured":"Leroy, E. et al. His499 Regulates Dimerization and Prevents Oncogenic Activation by Asparagine Mutations of the Human Thrombopoietin Receptor. J. Biol. Chem. 291(6), 2974\u20132987 (2016).","journal-title":"J. Biol. Chem."},{"issue":"9","key":"62555_CR34","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.4049\/jimmunol.1201476","volume":"189","author":"P Pandiyan","year":"2012","unstructured":"Pandiyan, P. et al. The role of IL-15 in activating STAT5 and fine-tuning IL-17A production in CD4 T lymphocytes. J. Immunol. 189(9), 4237\u20134246 (2012).","journal-title":"J. Immunol."},{"key":"62555_CR35","doi-asserted-by":"publisher","first-page":"1362904","DOI":"10.3389\/fimmu.2024.1362904","volume":"15","author":"T Soltantoyeh","year":"2024","unstructured":"Soltantoyeh, T. et al. Simultaneous targeting of Tim3 and A2a receptors modulates MSLN-CAR T cell antitumor function in a human cervical tumor xenograft model. Front. Immunol. 15, 1362904 (2024).","journal-title":"Front. Immunol."},{"issue":"1","key":"62555_CR36","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13046-020-01546-6","volume":"39","author":"E Masoumi","year":"2020","unstructured":"Masoumi, E. et al. Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells. J. Exp. Clin. Cancer Res. 39(1), 49 (2020).","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"4","key":"62555_CR37","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer. 12(4), 252\u2013264 (2012).","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"62555_CR38","doi-asserted-by":"publisher","first-page":"101085","DOI":"10.1016\/j.tranon.2021.101085","volume":"14","author":"X Liu","year":"2021","unstructured":"Liu, X. et al. A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory\/relapsed B cell lymphoma. Transl Oncol. 14(7), 101085 (2021).","journal-title":"Transl Oncol."},{"issue":"6","key":"62555_CR39","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","volume":"76","author":"X Liu","year":"2016","unstructured":"Liu, X. et al. A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. Cancer Res. 76(6), 1578\u20131590 (2016).","journal-title":"Cancer Res."},{"key":"62555_CR40","doi-asserted-by":"crossref","unstructured":"Shen, C., Zhang, Z. & Zhang, Y. Chimeric antigen receptor T cell exhaustion during treatment for hematological malignancies. Biomed. Res. Int. 2020,  8765028  (2020).","DOI":"10.1155\/2020\/8765028"},{"issue":"1","key":"62555_CR41","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12935-023-02948-0","volume":"23","author":"B Akbari","year":"2023","unstructured":"Akbari, B. et al. The inhibitory receptors PD1, Tim3, and A2aR are highly expressed during mesoCAR T cell manufacturing in advanced human epithelial ovarian cancer. Cancer Cell. Int. 23(1), 104 (2023).","journal-title":"Cancer Cell. Int."},{"issue":"1","key":"62555_CR42","doi-asserted-by":"publisher","first-page":"8370","DOI":"10.1038\/s41598-022-12136-1","volume":"12","author":"I Wieleba","year":"2022","unstructured":"Wieleba, I. et al. In vitro preliminary study on different anti-PD-1 antibody concentrations on T cells activation. Sci. Rep. 12(1), 8370 (2022).","journal-title":"Sci. Rep."},{"issue":"9","key":"62555_CR43","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1158\/2326-6066.CIR-14-0040","volume":"2","author":"C Wang","year":"2014","unstructured":"Wang, C. et al. In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates. Cancer Immunol. Res. 2(9), 846\u2013856 (2014).","journal-title":"Cancer Immunol. Res."},{"issue":"3","key":"62555_CR44","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1002\/eji.1830250328","volume":"25","author":"C Vincent","year":"1995","unstructured":"Vincent, C. et al. Specific hyporesponsiveness of alloreactive peripheral T cells induced by CD4 antibodies. Eur. J. Immunol. 25(3), 816\u2013822 (1995).","journal-title":"Eur. J. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62555-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62555-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62555-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:02:30Z","timestamp":1792065750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62555-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["62555"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-62555-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7582501\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"32368"}}